| Sanara Rene Coleman, LCSW | |
|
1822 W 2nd St, Crowley, LA 70526-4720 | |
| (337) 788-7511 | |
| (337) 788-7588 |
| Full Name | Sanara Rene Coleman |
|---|---|
| Gender | Female |
| Speciality | Clinical Social Worker |
| Experience | 14 Years |
| Location | 1822 W 2nd St, Crowley, Louisiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457992901 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 11181 (Louisiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Acadiana Area Human Services District | 7517198047 | 23 |
News Archive
Infrastructure Ontario and Humber River Regional Hospital today released a request for qualifications to design, build, finance and maintain its new acute care hospital.
Delphi Genetics SA has announced today a broad licensing agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for the use of the StabyExpress technology, which allows high yield, cost effective protein expression without the use of antibiotics.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.
Operating as a division of DaVita Inc., a leading provider of kidney care services for those diagnosed with end stage renal disease and chronic kidney disease, DVA Laboratory Services announced its new company name, DaVita Labs.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
› Verified 5 days ago
| Entity Name | Acadiana Area Human Services District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104253467 PECOS PAC ID: 7517198047 Enrollment ID: O20140327000122 |
News Archive
Infrastructure Ontario and Humber River Regional Hospital today released a request for qualifications to design, build, finance and maintain its new acute care hospital.
Delphi Genetics SA has announced today a broad licensing agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for the use of the StabyExpress technology, which allows high yield, cost effective protein expression without the use of antibiotics.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.
Operating as a division of DaVita Inc., a leading provider of kidney care services for those diagnosed with end stage renal disease and chronic kidney disease, DVA Laboratory Services announced its new company name, DaVita Labs.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sanara Rene Coleman, LCSW 1822 W 2nd St, Crowley, LA 70526-4720 Ph: (337) 788-7511 | Sanara Rene Coleman, LCSW 1822 W 2nd St, Crowley, LA 70526-4720 Ph: (337) 788-7511 |
News Archive
Infrastructure Ontario and Humber River Regional Hospital today released a request for qualifications to design, build, finance and maintain its new acute care hospital.
Delphi Genetics SA has announced today a broad licensing agreement with a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada, for the use of the StabyExpress technology, which allows high yield, cost effective protein expression without the use of antibiotics.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.
Operating as a division of DaVita Inc., a leading provider of kidney care services for those diagnosed with end stage renal disease and chronic kidney disease, DVA Laboratory Services announced its new company name, DaVita Labs.
Biotechnology company MabCure, Inc. today announced that a confirmatory study demonstrated the company's proprietary monoclonal antibodies (MAbs) successfully identified ovarian cancer in blood (94 percent accuracy) and with no false positives or cross-reactions with benign ovarian tumors or healthy blood. MabCure's serum diagnostic test is the first to recognize unique tumor markers or cancer fingerprints present only in ovarian cancer, the deadliest of all gynecological cancers.
› Verified 5 days ago
Mrs. Carolyn R Knowles, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1822 West Second St, P.o. Drawer 1403, Crowley, LA 70527 Phone: 337-788-7511 Fax: 337-788-7588 | |
Mrs. Allison Cara Kidder, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 713 N Avenue L, Crowley, LA 70526 Phone: 337-788-3330 Fax: 337-788-4770 | |
Heather R Prejean, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 318 E Park St, Crowley, LA 70526 Phone: 337-258-5214 Fax: 337-785-1188 | |
Mandi Jo Melton, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 318 E Park St, Crowley, LA 70526 Phone: 337-280-0539 Fax: 337-785-1188 | |
Amanda Richard Dupre', LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 21 Henrietta Dr, Crowley, LA 70526 Phone: 337-384-8876 Fax: 337-250-4676 | |
Ms. Demitra D Tsoukatos, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 6426 Lyons Point Hwy, Crowley, LA 70526 Phone: 337-501-4345 |